

13. The antibody or the antigen binding fragment thereof of claim **1**, wherein the antibody or the antigen-binding fragment thereof is humanized or partially humanized.

14. The antibody or the antigen binding fragment thereof of claim **1**, wherein the antibody is POCmAb.

15. A composition, comprising the antibody or the antigen binding fragment thereof of claim **1** and a pharmaceutically acceptable diluent, carrier, or excipient.

16. A method of inhibiting tumor growth of a tumor expressing O-glycan mucin-type glycoprotein MUC16 in a subject in need thereof, comprising administering to the subject the antibody or the antigen binding fragment thereof that targets O-glycan mucin-type glycoprotein MUC16 claim **1**.

17. The method of claim **16**, wherein the antibody or the antigen binding fragment thereof is an antibody.

18. The method of claim **17**, wherein the antibody is a monoclonal antibody.

19-20. (canceled)

21. The method of claim **6**, further comprising administering a second therapeutic agent comprising at least one of

a cytotoxic agent, an additional antibody or a therapeutically active fragment thereof, or a chemotherapy regimen.

22. The method of claims **21**, wherein the cytotoxic agent is at least one of an inhibitor of ErbB signaling, an inhibitor of phosphoinositide 3-kinases (PI3Ks)/Akt signaling, gemcitabine and abraxane or combinations thereof;

wherein the additional antibody or therapeutically fragment thereof is oregovomab antibody B43.13, AR9.6 antibody, or combinations thereof; and

wherein the chemotherapy regimen is Folfirinox.

23-26. (canceled)

27. The method of claim **16**, wherein the tumor is chosen from a pancreatic tumor, a gall bladder tumor, a gastric tumor, a colon tumor, an ovarian tumor, a breast tumor, and a liver tumor.

28. The method of claim **16**, wherein the method is for the treatment of a cancer.

29-63. (canceled)

* * * * *